FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3049761941> ?p ?o ?g. }

• W3049761941 endingPage "62" @default.
• W3049761941 startingPage "53" @default.
• W3049761941 abstract "Vantictumab is a monoclonal antibody that binds to frizzled (FZD) receptors and inhibits canonical WNT signaling. This phase Ib dose escalation study enrolled patients with locally recurrent or metastatic HER2-negative breast cancer who were treated with weekly paclitaxel in combination with escalating doses of vantictumab. Patients were enrolled in dose escalation cohorts treated with weekly paclitaxel 90 mg/m2 on days 1, 8 and 15 in combination with vantictumab 3.5–14 mg/kg days 1 and 15 or 3–8 mg/kg day 1 of every 28-day cycle. Primary endpoints were safety, dose-limiting toxicities (DLTs). Secondary endpoints included pharmacokinetics, efficacy and an exploratory biomarker analysis. Forty-eight female patients with a mean age of 54 were enrolled. The majority (66.6%) received prior chemotherapy for recurrent or metastatic disease; 45.8% were hormone receptor (HR)-positive, HER2-negative and 54.2% triple-negative. The most frequent adverse events related to any study treatment were nausea (54.2%), alopecia (52.1%), fatigue (47.9%), and peripheral neuropathy (43.8%). No DLTs occurred; however, 6 patients experienced fractures outside of the DLT window. The overall response rate was 31.3% and the clinical benefit rate was 68.8%. A 6-gene WNT pathway signature showed significant association with progression-free survival (PFS) and overall survival (OS) for the biomarker high versus biomarker low groups (PFS: p = 0.029 and OS: p = 0.00045, respectively). The combination of vantictumab and weekly paclitaxel was generally well tolerated with promising efficacy; however, the incidence of fractures limits future clinical development of this particular WNT inhibitor in metastatic breast cancer. ClinicalTrials.gov registration: NCT01973309" @default.
• W3049761941 created "2020-08-21" @default.
• W3049761941 creator A5000961519 @default.
• W3049761941 creator A5003433691 @default.
• W3049761941 creator A5014963560 @default.
• W3049761941 creator A5015961133 @default.
• W3049761941 creator A5022759974 @default.
• W3049761941 creator A5024641368 @default.
• W3049761941 creator A5028833538 @default.
• W3049761941 creator A5041912334 @default.
• W3049761941 creator A5054620736 @default.
• W3049761941 creator A5063550429 @default.
• W3049761941 creator A5072954656 @default.
• W3049761941 creator A5079509906 @default.
• W3049761941 creator A5080530418 @default.
• W3049761941 creator A5086038672 @default.
• W3049761941 creator A5091654892 @default.
• W3049761941 date "2020-08-14" @default.
• W3049761941 modified "2023-10-05" @default.
• W3049761941 title "Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer" @default.
• W3049761941 cites W1996583924 @default.
• W3049761941 cites W2019196925 @default.
• W3049761941 cites W2029456301 @default.
• W3049761941 cites W2069750786 @default.
• W3049761941 cites W2084429573 @default.
• W3049761941 cites W2116610925 @default.
• W3049761941 cites W2126275851 @default.
• W3049761941 cites W2139248078 @default.
• W3049761941 cites W2155507705 @default.
• W3049761941 cites W2547100318 @default.
• W3049761941 cites W2601321887 @default.
• W3049761941 cites W2630941289 @default.
• W3049761941 cites W2760010857 @default.
• W3049761941 cites W2802611781 @default.
• W3049761941 cites W2948146865 @default.
• W3049761941 cites W2963418546 @default.
• W3049761941 cites W4239051461 @default.
• W3049761941 doi "https://doi.org/10.1007/s10549-020-05817-w" @default.
• W3049761941 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7572714" @default.
• W3049761941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32803633" @default.
• W3049761941 hasPublicationYear "2020" @default.
• W3049761941 type Work @default.
• W3049761941 sameAs 3049761941 @default.
• W3049761941 citedByCount "56" @default.
• W3049761941 countsByYear W30497619412020 @default.
• W3049761941 countsByYear W30497619412021 @default.
• W3049761941 countsByYear W30497619412022 @default.
• W3049761941 countsByYear W30497619412023 @default.
• W3049761941 crossrefType "journal-article" @default.
• W3049761941 hasAuthorship W3049761941A5000961519 @default.
• W3049761941 hasAuthorship W3049761941A5003433691 @default.
• W3049761941 hasAuthorship W3049761941A5014963560 @default.
• W3049761941 hasAuthorship W3049761941A5015961133 @default.
• W3049761941 hasAuthorship W3049761941A5022759974 @default.
• W3049761941 hasAuthorship W3049761941A5024641368 @default.
• W3049761941 hasAuthorship W3049761941A5028833538 @default.
• W3049761941 hasAuthorship W3049761941A5041912334 @default.
• W3049761941 hasAuthorship W3049761941A5054620736 @default.
• W3049761941 hasAuthorship W3049761941A5063550429 @default.
• W3049761941 hasAuthorship W3049761941A5072954656 @default.
• W3049761941 hasAuthorship W3049761941A5079509906 @default.
• W3049761941 hasAuthorship W3049761941A5080530418 @default.
• W3049761941 hasAuthorship W3049761941A5086038672 @default.
• W3049761941 hasAuthorship W3049761941A5091654892 @default.
• W3049761941 hasBestOaLocation W30497619412 @default.
• W3049761941 hasConcept C121608353 @default.
• W3049761941 hasConcept C126322002 @default.
• W3049761941 hasConcept C143998085 @default.
• W3049761941 hasConcept C185592680 @default.
• W3049761941 hasConcept C203092338 @default.
• W3049761941 hasConcept C2775930923 @default.
• W3049761941 hasConcept C2776694085 @default.
• W3049761941 hasConcept C2777292972 @default.
• W3049761941 hasConcept C2779984678 @default.
• W3049761941 hasConcept C2781197716 @default.
• W3049761941 hasConcept C31760486 @default.
• W3049761941 hasConcept C530470458 @default.
• W3049761941 hasConcept C535046627 @default.
• W3049761941 hasConcept C55493867 @default.
• W3049761941 hasConcept C71924100 @default.
• W3049761941 hasConcept C90924648 @default.
• W3049761941 hasConceptScore W3049761941C121608353 @default.
• W3049761941 hasConceptScore W3049761941C126322002 @default.
• W3049761941 hasConceptScore W3049761941C143998085 @default.
• W3049761941 hasConceptScore W3049761941C185592680 @default.
• W3049761941 hasConceptScore W3049761941C203092338 @default.
• W3049761941 hasConceptScore W3049761941C2775930923 @default.
• W3049761941 hasConceptScore W3049761941C2776694085 @default.
• W3049761941 hasConceptScore W3049761941C2777292972 @default.
• W3049761941 hasConceptScore W3049761941C2779984678 @default.
• W3049761941 hasConceptScore W3049761941C2781197716 @default.
• W3049761941 hasConceptScore W3049761941C31760486 @default.
• W3049761941 hasConceptScore W3049761941C530470458 @default.
• W3049761941 hasConceptScore W3049761941C535046627 @default.
• W3049761941 hasConceptScore W3049761941C55493867 @default.
• W3049761941 hasConceptScore W3049761941C71924100 @default.
• W3049761941 hasConceptScore W3049761941C90924648 @default.
• W3049761941 hasFunder F4320337351 @default.

• next